Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Natural killer cell alloreactivity for leukemia therapy.

Loredana Ruggeri1, Antonella Mancusi, Katia Perruccio

  • 1Division of Hematology and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Perugia, 06122 Perugia, Italy.

Journal of Immunotherapy (Hagerstown, Md. : 1997)
|April 20, 2005
PubMed
Summary

Natural killer (NK) cell alloreactivity arises from mismatches in human leukocyte antigen (HLA) class I molecules between donor and recipient. NK cell alloreactive haploidentical donor transplantation effectively controls acute myeloid leukemia relapse and improves engraftment while preventing graft-versus-host disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Durable remission despite transplantation with active disease in therapy-related NUP98::TOP1-rearranged acute myeloid leukemia.

Annals of hematology·2026
Same author

A specific stem cell program and CD112 immunological axis dysfunctions underpinning monosomy 7-associated myeloid neoplasms.

Signal transduction and targeted therapy·2026
Same author

Cefiderocol in Children with Hematologic Malignancies-The Multicenter Retrospective Experience of the Infection Working Group of the Italian Pediatric Hematology and Oncology Association (AIEOP).

Journal of clinical medicine·2026
Same author

Characteristics and Outcome of Patients With Refractory Orbital Rhabdomyosarcoma.

Head & neck·2026
Same author

Lactoferrin reduces febrile neutropenia in children receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled trial.

Haematologica·2026
Same author

Physical Activity as a Tool for Social Inclusion in Multiple Sclerosis: A Systematic Review of Qualitative, Quantitative, and Mixed-Methods Evidence.

Sports (Basel, Switzerland)·2026

Area of Science:

  • Immunology
  • Transplantation immunology
  • Cancer immunotherapy

Background:

  • Natural killer (NK) cell alloreactivity is triggered by a mismatch between donor NK cell inhibitory receptors and recipient human leukocyte antigen (HLA) class I molecules.
  • Donor NK cells recognize the absence of self-HLA class I on allogeneic targets, leading to NK cell-mediated alloreactions.
  • Haploidentical NK cell transplantation has shown promise in managing hematologic malignancies.

Purpose of the Study:

  • To elucidate the mechanisms underlying donor NK cell alloreactivity.
  • To evaluate the efficacy of NK cell alloreactive haploidentical donor transplantation in controlling acute myeloid leukemia (AML) relapse.
  • To assess the impact of this transplantation strategy on engraftment and graft-versus-host disease (GVHD).

Main Methods:

Related Experiment Videos

  • Analysis of NK cell receptor interactions with mismatched HLA class I ligands.
  • Assessment of NK cell-mediated cytotoxicity against allogeneic targets.
  • Clinical evaluation of outcomes in patients undergoing haploidentical NK cell transplantation for AML.

Main Results:

  • Donor NK cell alloreactivity is mediated by specific inhibitory receptors sensing the lack of self-HLA class I on recipient cells.
  • Transplantation using NK cell alloreactive haploidentical donors successfully controlled AML relapse.
  • Improved engraftment and a significant reduction in graft-versus-host disease were observed.

Conclusions:

  • Donor-versus-recipient NK cell alloreactivity is a key mechanism in allogeneic transplantation, driven by HLA class I mismatches.
  • NK cell alloreactive haploidentical donor transplantation represents a promising strategy for AML treatment, offering graft-versus-leukemia effects without GVHD.
  • This approach enhances engraftment and controls disease relapse, highlighting the therapeutic potential of NK cells in transplantation.